drugset / Trial / NCT04684394
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.
Timeline
- Start
- 2020-12-29
- Primary completion
- 2022-01-10
- Completion
- 2022-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEM103 | Protein / enzyme biologic | 500 ug | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |